瑞格非尼治疗难治性转移性结肠癌疗效与安全性的Meta分析  

Meta-analysis on the efficacy and safety of regorafenib in the treatment of refractory metastatic colon cancer

作　　者：雷鑫明 黎红光[1] 吴深宝[1] 庄李磊[1] 陆小锋 傅志成 LEI Xinming;LI Hongguang;WU Shenbao;ZHUANG Lilei;LU Xiaofeng;FU Zhicheng(Department of Gastroenterology,Yiwu Central Hospital in Zhejiang Province,Yiwu322000,China)

机构地区：[1]浙江省义乌市中心医院消化内科,浙江义乌322000

出　　处：《中国现代医生》2020年第5期25-29,33,共6页China Modern Doctor

基　　金：浙江省科技计划项目(2017C33179)。

摘　　要：目的探讨瑞格非尼在难治性转移性结肠癌(Patients with metastatic colorectal cancer,mCRC)中的疗效和安全性。方法检索瑞格非尼治疗难治性转移性结直肠癌的对照试验,年限为2009~2019年,采用Revman 5.3软件进行系统Meta分析。结果本研究经过系统的筛选和评价,总共5篇文献符合标准。Meta分析结果表明:在3年总生存率和3年无瘤生存率方面,瑞格非尼组患者的生存率高于对照组,差异有统计学意义(P<0.05)。在不良反应方面,瑞格非尼组患者发生率低于对照组,差异有统计学意义(P<0.05)。结论瑞格非尼治疗难治性转移性结肠癌疗效好且安全性高。Objective To investigate the efficacy and safety of regorafenib in the patients with refractory metastatic colorectal cancer(mCRC).Methods A controlled trial of regorafenib in the treatment of refractory metastatic colorectal cancer was performed.The period was from 2009 to 2019,and the literature articles were screened and evaluated according to the quality evaluation criteria in the Cochrane System Evaluation Manual.Systematic meta-analysis was performed using Revman 5.3 software.Results A total of 5 articles were included in the study.Meta-analysis showed that the 3-year overall survival rate and the 3-year tumor-free survival rate in the regorafenib group were higher than those in the control group,and the differences were statistically significant(P<0.05).The incidence rate of adverse reactions in the regorafenib group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Regorafenib has a favorable efficacy and high safety in the treatment of refractory metastatic colon cancer.

关 键 词：难治性 转移性 结肠癌 瑞格非尼 META分析 

分 类 号：R735.3[医药卫生—肿瘤]